Compare
Veracyte, Inc. vs Castle Biosciences Inc vs Caris Life Sciences, Inc. vs Fulgent Genetics, Inc.
| Latest fiscal year | Veracyte, Inc. VCYT | Castle Biosciences Inc CSTL | Caris Life Sciences, Inc. CAI | Fulgent Genetics, Inc. FLGT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $517.14M | $344.23M | $812.03M | $322.67M |
| Revenue growth (YoY) | +16.0% | +3.7% | +97.0% | +13.8% |
| Gross margin | 70.1% | 79.4% (computed) | n/a | 40.6% |
| Operating margin | 11.2% | -12.4% | 5.6% | -28.2% |
| Net margin | 12.8% | -7.0% | -8.4% | -18.8% |
| Net income | $66.35M | -$24.16M | -$68.09M | -$60.51M |
| EPS (Diluted) | $0.82 | -$0.83 | -$3.22 | n/a |
| Operating cash flow | $136.31M | $64.35M | $83.16M | -$101.64M |
| Free cash flow | $126.63M | $28.33M | $66.89M | -$124.21M |
| Cash & equivalents | $362.58M | $116.73M | $796.27M | $50.19M |
| Total assets | $1.41B | $578.56M | $1.13B | $1.21B |
| Total liabilities | $96.44M | $107.68M | $548.36M | $106.81M |
| Shareholders' equity | $1.31B | $470.87M | $577.31M | $1.11B |
| Return on year-end equity | 5.1% | -5.1% | -11.8% | -5.4% |
| Shares outstanding | 79.36M | 29.69M | 282.53M | 31.08M |
Revenue, most recent five fiscal years
| Fiscal year | Veracyte, Inc. | Castle Biosciences Inc | Caris Life Sciences, Inc. | Fulgent Genetics, Inc. |
|---|---|---|---|---|
| Latest | $517.14M Ended 2025-12-31 | $344.23M Ended 2025-12-31 | $812.03M Ended 2025-12-31 | $322.67M Ended 2025-12-31 |
| 1 year earlier | $445.76M Ended 2024-12-31 | $332.07M Ended 2024-12-31 | $412.26M Ended 2024-12-31 | $283.47M Ended 2024-12-31 |
| 2 years earlier | $361.05M Ended 2023-12-31 | $219.79M Ended 2023-12-31 | $306.13M Ended 2023-12-31 | $289.21M Ended 2023-12-31 |
| 3 years earlier | $296.54M Ended 2022-12-31 | $137.04M Ended 2022-12-31 | n/a | $618.97M Ended 2022-12-31 |
| 4 years earlier | $219.51M Ended 2021-12-31 | $94.08M Ended 2021-12-31 | n/a | $992.58M Ended 2021-12-31 |